$0.67
+0.02 (+2.48%)
Open$0.66
Previous Close$0.66
Day High$0.68
Day Low$0.62
52W High$4.13
52W Low$0.83
Volume—
Avg Volume45.6K
Market Cap1.69M
P/E Ratio—
EPS$-2.51
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,042.5% upside
Current
$0.67
$0.67
Target
$21.19
$21.19
$14.35
$21.19 avg
$22.63
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 842.6K | 775.9K | 707.6K |
| Net Income | 53.5K | 41.0K | 38.8K |
| Profit Margin | 6.3% | 5.3% | 5.5% |
| EBITDA | 84.6K | 70.9K | 63.0K |
| Free Cash Flow | 39.3K | 30.9K | 34.5K |
| Rev Growth | +2.0% | +16.5% | +21.7% |
| Debt/Equity | 0.16 | 0.21 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |